Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease

Brain Research

Volumn 1276, Issue , 2009, Pages 39-49

  Andereggen, Lukas ^a   Meyer, Morten ^b   Guzman, Raphael ^c   Ducray, Angélique D ^a   Widmer, Hans Rudolf ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glial cell line derived neurotrophic factor; Parkinson's disease; Rat; Transplantation; Tyrosine hydroxylase; Ventral mesencephalic organotypic culture

Indexed keywords

DEXAMPHETAMINE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; EMBRYO; FEMALE; GRAFT SURVIVAL; IMMUNOREACTIVITY; MESENCEPHALON; NERVE CELL; NERVE FIBER GROWTH; NONHUMAN; ORGAN CULTURE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; TISSUE CULTURE;

AMPHETAMINE; ANIMALS; BRAIN; CELL SURVIVAL; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 67349133927     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.04.021     Document Type: Article

References (72)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94 (1946) 239-247
2. Ahlskog J.E. Beating a dead horse: dopamine and Parkinson disease. Neurology 69 (2007) 1701-1711
3. Akerud P., Alberch J., Eketjall S., Wagner J., and Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J. Neurochem. 73 (1999) 70-78
4. Alexi T., Borlongan C.V., Faull R.L., Williams C.E., Clark R.G., Gluckman P.D., and Hughes P.E. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 60 (2000) 409-470
5. Apostolides C., Sanford E., Hong M., and Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 83 (1998) 363-372
6. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., Leitner M.L., Araki T., Johnson Jr. E.M., and Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 (1998) 1291-1302
7. Bauer M., Suppmann S., Meyer M., Hesslinger C., Gasser T., Widmer H.R., and Ueffing M. Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones. J. Neurochem. 82 (2002) 1300-1310
8. Beck K.D., Knusel B., and Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 52 (1993) 855-866
9. Bensadoun J.C., Deglon N., Tseng J.L., Ridet J.L., Zurn A.D., and Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164 (2000) 15-24
10. Bjorklund A. Neurobiology. Better cells for brain repair. Nature 362 (1993) 414-415
11. Bjorklund A., Stenevi U., Dunnett S.B., and Gage F.H. Cross-species neural grafting in a rat model of Parkinson's disease. Nature 298 (1982) 652-654
12. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., and Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886 (2000) 82-98
13. Borgal L., Hong M., Sadi D., and Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience 147 (2007) 712-719
14. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., and Granholm A.C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355 (1995) 479-489
15. Braak H., and Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat. Med. 14 (2008) 483-485
16. Brundin P., Barbin G., Strecker R.E., Isacson O., Prochiantz A., and Bjorklund A. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro. Brain Res. 467 (1988) 233-243
17. Brundin P., Karlsson J., Emgard M., Schierle G.S., Hansson O., Petersen A., and Castilho R.F. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9 (2000) 179-195
18. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., and Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 Pt 7 (2000) 1380-1390
19. Cenci M.A., Kalen P., Duan W.M., and Bjorklund A. Transmitter release from transplants of fetal ventral mesencephalon or locus coeruleus in the rat frontal cortex and nucleus accumbens: effects of pharmacological and behaviorally activating stimuli. Brain Res. 641 (1994) 225-248
20. Chen X., Liu W., Guoyuan Y., Liu Z., Smith S., Calne D.B., and Chen S. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. Parkinsonism Relat. Disord. 10 (2003) 1-7
21. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., Zufferey R., Trono D., and Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11 (2000) 179-190
22. Dowd E., Monville C., Torres E.M., Wong L.F., Azzouz M., Mazarakis N.D., and Dunnett S.B. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur. J. Neurosci. 22 (2005) 2587-2595
23. Dunnett S.B. Transplantation of embryonic dopamine neurons: what we know from rats. J. Neurol. 238 (1991) 65-74
24. In: Dunnett S., and Björklund A. (Eds). Staging and Dissection of Rat Embryos (1992), Oxford Univ Press, Oxford
25. Dunnett S.B., Bjorklund A., Stenevi U., and Iversen S.D. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 229 (1981) 209-217
26. Dunnett S.B., Bjorklund A., Stenevi U., and Iversen S.D. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215 (1981) 147-161
27. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., and Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
28. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., and Bartus R.T. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Molec. Ther. 15 (2007) 62-68
29. Gueritaud J.P., and Seyfritz N. An organotypic co-culture of embryonic rat brainstem and tongue or skeletal muscle. Eur. J. Neurosci. 4 (1992) 616-627
30. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., and Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56 (1999) 179-187
31. Hebb A.O., Hebb K., Ramachandran A.C., and Mendez I. Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage. J. Neurosurg. 98 (2003) 1078-1083
32. Hoglinger G.U., Sautter J., Meyer M., Spenger C., Seiler R.W., Oertel W.H., and Widmer H.R. Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Res. 813 (1998) 313-322
33. Hoglinger G.U., Widmer H.R., Spenger C., Meyer M., Seiler R.W., Oertel W.H., and Sautter J. Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 167 (2001) 148-157
34. Hou J.G., Lin L.F., and Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66 (1996) 74-82
35. Jensen P., Pedersen E.G., Zimmer J., Widmer H.R., and Meyer M. Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease. Brain Res. 1218 (2008) 13-20
36. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease. Curr. Opin. Investig. Drugs 5 (2004) 720-726
37. Kearns C.M., Cass W.A., Smoot K., Kryscio R., and Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J. Neurosci. 17 (1997) 7111-7118
38. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
39. Kirik D., Rosenblad C., Bjorklund A., and Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20 12 (2000) 4686-4700
40. Kirik D., Georgievska B., and Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7 (2004) 105-110
41. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sanberg P.R., Hauser R.A., Smith D.A., Nauert G.M., Perl D.P., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332 (1995) 1118-1124
42. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., Martel L., Levey A.E., Mufson E.J., Freeman T.B., and Olanow C.W. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370 (1996) 203-230
43. Kordower J.H., Freeman T.B., Chen E.Y., Mufson E.J., Sanberg P.R., Hauser R.A., Snow B., and Olanow C.W. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 13 (1998) 383-393
44. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
45. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell III J., Gasmi M., and Bartus R.T. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 60 (2006) 706-715
46. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson Jr. E.M., and Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
47. Kuan W.L., and Barker R.A. New therapeutic approaches to Parkinson's disease including neural transplants. Neurorehabilitation Neural Repair 19 (2005) 155-181
48. Laguna Goya R., Tyers P., and Barker R.A. The search for a curative cell therapy in Parkinson's disease. J. Neurol. Sci. 265 (2008) 32-42
49. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59 (2006) 591-596
50. Lapchak P.A., Araujo D.M., Hilt D.C., Sheng J., and Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res. 777 (1997) 153-160
51. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
52. Lindvall O., and Bjorklund A. Cell therapy in Parkinson's disease. NeuroRx 1 (2004) 382-393
53. Mandel R.J., Brundin P., and Bjorklund A. The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur. J. Neurosci. 2 (1990) 888-894
54. Masure S., Cik M., Pangalos M.N., Bonaventure P., Verhasselt P., Lesage A.S., Leysen J.E., and Gordon R.D. Molecular cloning, expression and tissue distribution of glial-cell-line-derived neurotrophic factor family receptor alpha-3 (GFRalpha-3). Eur. J. Biochem. 251 (1998) 622-630
55. Matarredona E.R., Meyer M., Seiler R.W., and Widmer H.R. CGP 3466 increases survival of cultured fetal dopaminergic neurons. Restor. Neurol. Neurosci. 21 (2003) 29-37
56. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., Weerasinghe S., King D., Desrosiers J., Darvesh S., Acorn T., and Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J. Neurosurg. 92 (2000) 863-869
57. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., Dagher A., and Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128 (2005) 1498-1510
58. Meyer M., Widmer H.R., Wagner B., Guzman R., Evtouchenko L., Seiler R.W., and Spenger C. Comparison of mesencephalic free-floating tissue culture grafts and cell suspension grafts in the 6-hydroxydopamine-lesioned rat. Exp. Brain Res. 119 (1998) 345-355
59. Meyer M., Matarredona E.R., Seiler R.W., Zimmer J., and Widmer H.R. Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures. Neuroscience 108 (2001) 273-284
60. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., Lampe P.A., Heuckeroth R.O., Kotzbauer P.T., Simburger K.S., Golden J.P., Davies J.A., Vejsada R., Kato A.C., Hynes M., Sherman D., Nishimura M., Wang L.C., Vandlen R., Moffat B., Klein R.D., Poulsen K., Gray C., Garces A., Johnson Jr. E.M., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 (1998) 245-253
61. Nikkhah G., Cunningham M.G., Jodicke A., Knappe U., and Bjorklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res. 633 (1994) 133-143
62. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., and Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003) 403-414
63. Saarma M. GDNF - a stranger in the TGF-beta superfamily?. Eur. J. Biochem. 267 (2000) 6968-6971
64. Sauer H.J., and Brundin A. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Restor. Neurol. Neurosci. 2 (1991) 123-125
65. Sauer H.J., Frodl E.M., Kupsch A., ten Bruggencate G., and Oertel W.H. Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease. Exp. Brain Res. 90 (1992) 54-62
66. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., and Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149 (1998) 230-236
67. Schaller B., Andres R.H., Huber A.W., Meyer M., Perez-Bouza A., Ducray A.D., Seiler R.W., and Widmer H.R. Effect of GDNF on differentiation of cultured ventral mesencephalic dopaminergic and non-dopaminergic calretinin-expressing neurons. Brain Res. 1036 (2005) 163-172
68. Spenger C., Studer L., Evtouchenko L., Egli M., Burgunder J.M., Markwalder R., and Seiler R.W. Long-term survival of dopaminergic neurones in free-floating roller tube cultures of human fetal ventral mesencephalon. J. Neurosci. Methods 54 (1994) 63-73
69. Spenger C., Hyman C., Studer L., Egli M., Evtouchenko L., Jackson C., Dahl-Jorgensen A., Lindsay R.M., and Seiler R.W. Effects of BDNF on dopaminergic, serotonergic, and GABAergic neurons in cultures of human fetal ventral mesencephalon. Exp. Neurol. 133 (1995) 50-63
70. Thompson L., Barraud P., Andersson E., Kirik D., and Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25 (2005) 6467-6477
71. Widmer H.R., Schaller B., Meyer M., and Seiler R.W. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured ventral mesencephalic calbindin- and calretinin-expressing neurons. Exp. Neurol. 164 (2000) 71-81
72. Zihlmann K.B., Ducray A.D., Schaller B., Huber A.W., Krebs S.H., Andres R.H., Seiler R.W., Meyer M., and Widmer H.R. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res. Bull. 68 (2005) 42-53